StockUS listing USRGEDFPINKHealthcareQuality Compounder

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt(RGEDF) Stock Analysis | Healthcare

USD --+0.00%
Reward70High
Risk12Low
75%Data
Strong 25% profit margin · Revenue growing 13% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 7.91Bn
Reward Ratingⓘ70 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ12 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RGEDF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt?

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products.

AI Brief Pro

The brief on Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt?

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 7.91B, and a P/E ratio of 10.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (70)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio10.4728
Beta0.325
Insider Activity
12M windowNo data
No insider activity data available for this ticker.